Several mechanisms, including a T790M mutation in the EGFR, MET amplification, and overexpression of hepatocyte growth factor (HGF), induce acquired resistance to reversible EGFR-TKIs for NSCLC with EGFR-activating mutations [6]–[8]. Here, HGF is linked to non-small cell lung carcinoma.